GB Patent

GB2397025A — Devices to deliver substances to the mucosa of the nose or mouth

Assigned to Optinose AS · Expires 2004-07-14 · 22y expired

What this patent protects

A delivery device and method for delivering substances as an aerosol to a subject via the nasal or oral mucosae. The delivery device comprising a nozzle for directing the aerosol at the mucosa, and a substance supply unit, characterised in that at least a fraction of the aerosol …

USPTO Abstract

A delivery device and method for delivering substances as an aerosol to a subject via the nasal or oral mucosae. The delivery device comprising a nozzle for directing the aerosol at the mucosa, and a substance supply unit, characterised in that at least a fraction of the aerosol particles have a dimension and velocity such as to penetrate the mucosa. The nozzle may include a nosepiece which may be inflatable and has the effect of directing the aerosol at the mucosa. Actuation may be triggered in response to proximity to the mucosal surface or in response to breath or exhalation. A second delivery unit may deliver another substance to the other nostril. Also claimed is a delivery device comprising a nozzle and nosepiece wherein actuation is associated with initiation of the Hering-Breuer reflex by providing a flow of gas at the face of the user.

Drugs covered by this patent

Patent Metadata

Patent number
GB2397025A
Jurisdiction
GB
Classification
Expires
2004-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.